Skip to content
Open access

Multi‐Omics Analysis Reveals That Aβ42‐ Me3 Co‐Aggregation Induces Mitophagy Blockade in Early Stages of Alzheimer's Disease

Sep 2026 · MedComm · Vol 7 · 0 citations · 38 references
Medicine

TL;DR

This study provides mechanistic insight into early mitochondrial dysfunction in AD and identifies the Aβ‐Me3 axis, which functions not only as a metabolic responder to Aβ‐associated stress but also as a contributor to early mitochondrial pathology.

Abstract

Mitochondrial dysfunction is one of the earliest pathological features of Alzheimer's disease (AD), preceding overt neurodegeneration and cognitive decline. Amyloid‐β (Aβ) accumulation has long been considered a central pathogenic event in AD, yet how Aβ toxicity is mechanistically linked to mitochondrial impairment during early disease stages remains incompletely understood. To address this, we combined multi‐omics with in vivo and in vitro genetic interventions. Here, we show that malic enzyme 3 (Me3) links Aβ aggregation to mitochondrial dysfunction in APP/PS1 mice and neuronal cells. At ultra‐early and early AD stages (3 and 6 months), Me3 was upregulated and accumulated within mitochondria, where it colocalized with Aβ42 and physically interacted with it, an association linked to oxidative stress and impaired mitophagy. Knockdown of Me3 reduced mitochondrial reactive oxygen species, improved mitochondrial morphology, and alleviated mitophagy defects in both cellular and mouse models, with statistical significance across these functional measurements (p < 0.05). These results suggest that Me3 functions not only as a metabolic responder to Aβ‐associated stress but also as a contributor to early mitochondrial pathology. By identifying the Aβ‐Me3 axis, this study provides mechanistic insight into early mitochondrial dysfunction in AD, while further validation in human AD samples remains necessary.

Read PDF

Similar papers

Oct 2026

Icariin enhances PINK1-associated mitophagy to attenuate NLRP3/GSDMD-related microglial pyroptosis and cognitive impairment in Alzheimer's disease.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which microglia-mediated neuroinflammation contributes to disease progression. Icariin (ICA), a major bioactive flavonoid from Epimedium, has neuroprotective activity, but how it regulates mitochondrial quality control and inflammatory injury in mi...

Long-Min Fan, Hai-Tao Jiang, Min Yi et al. · 0 citations
Open access Sep 2026

MA-5 attenuates disease-associated transcriptomic aging and pathological microglial states in Gaucher disease

Overall, MA-5 suppresses neuroinflammation and reverses accelerated transcriptomic aging, supporting its potential as a therapeutic strategy for GD and other lysosomal storage disorders, as well as for diseases characterized by mitochondrial dysfunction, chronic inflammation, and pathological accumulation.

Y. Tongu, Tomoko Kasahara, Kohta Nakamura et al. · 0 citations
Sep 2026

Sephin1 directly targets PHB2 to activate PINK1-PRKN-dependent mitophagy and alleviate α-synuclein neurotoxicity in Parkinson's disease models.

Parkinson's disease (PD) is a prevalent age-related neurodegenerative disorder characterized by pathological α-synuclein aggregation, mitochondrial dysfunction, and progressive loss of dopaminergic neurons, with no effective disease-modifying treatment available. Sephin1 has been proven to exert protective effects in m...

Xv-shen Ding, Bao Wang, Zheng Han et al. · 0 citations
Open access Sep 2026

A brain-penetrant TRPML1 agonist enhances autophagy–lysosomal function and mitigates pathology in aged models of Parkinson’s and Alzheimer’s diseases

This work describes LW-1017, a potent, selective, and brain-penetrant small-molecule TRPML1 agonist and evaluates its pharmacodynamic activity and therapeutic effects in aged preclinical mouse models of Parkinson’s disease (PD) and Alzheimer’s disease (AD), supporting TRPML1 agonism as a promising strategy to counterac...

V. Cullen, Jun-Sheng Yang, Xiang-Yang Yu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.